Kyverna Therapeutics, Inc. (KYTX): Total Assets
$293.83M
As of 2025-12-31
$219.82M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $293.83M | -3.6% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $304.64M | +305.1% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $75.19M | n/a | 2025-03-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | 2025-12-31 | $293.83M | -3.6% |
| Alector, Inc. (ALEC) | 2025-12-31 | $293.24M | -37.4% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $290.46M | +98.3% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $305.88M | +42.1% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $276.88M | +113.8% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $318.94M | -27.6% |
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $268.69M | +82.9% |
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $261.04M | +70.7% |
| Replimune Group, Inc. (REPL) | 2026-03-31 | $332.39M | -39.7% |
Compare KYTX, ALEC, XFOR, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗